GPC-3, a carcinoembryonic proteoglycan on the tumor cell membrane, and CD133, an endothelial progenitor cell marker, are two popular immunotherapy targets in recent HCC research [190, 191]. The gene discussed is GPC3; the disease is neoplasm.